We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Natural Angiogenesis Inhibitors Slow Tumor Growth

By Biotechdaily staff writers
Posted on 28 Feb 2005
A recent report described the role played by naturally occurring inhibitors of angiogenesis (formation of new blood vessels) in the suppression of tumor growth.

Investigators at Harvard Medical School (Boston, MA, USA) used lines of mice genetically engineered to lack the genes for the endogenous angiogenesis inhibitors tumstatin, endostatin, or thrombospondin-1 (TSP-1). More...
A fourth line of mice lacked the genes for both tumstatin and TSP-1.

They found that normal physiologic levels of these inhibitors served to retard the growth of tumors, and that their absence led to enhanced angiogenesis and a two- to three-fold increase in tumor growth. Tumors grew twice as fast in the mice lacking both tumstatin and TSP-1, compared with either the tumstatin- or the TSP-1-deficient mice.

A fifth line of mice was engineered to overexpress the gene for endostatin, a situation mimicking human Down syndrome where the extra chromosome 21 produces about 1.6 times more endostatin than in normal individuals. Tumors in humans with Down syndrome are known to grow at an especially slow pace. Results of the current study published in the February 14, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences showed that tumors in this group of mice grew three times more slowly than did tumors in normal mice.

"Between nine and 10 million people worldwide die of cancer each year,” said senior author Dr. Raghu Kalluri, associate professor of medicine at Harvard Medical School. "While a lot has been learned of how genetic defects convert normal cells into cancerous cells, much less is known about how the body defends itself against the growth of cancer. Our study helps provide a glimpse into what may be happening. The hope is that this new understanding of cancer growth can eventually lead to the use of these natural proteins as therapies to treat cancer at an early stage, before it becomes a devastating disease.”




Related Links:
Harvard Medical School

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Electrolyte Analyzer
BKE-B
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.